Screener
BridgeBio Pharma BBIO Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $243.68M+120% | $194.52M+66.8% | $154.18M+2,521% | $120.7M+4,318% | $110.57M+5,000% | ||
| $15.05M+312% | $9.94M+277% | $8.11M+289% | $6.56M+997% | $3.65M+511% | ||
| $228.63M+114% | $184.58M+61.9% | $146.07M+3,746% | $114.14M+5,249% | $106.91M+6,710% | ||
| 93.8%-2.9pp | 94.9%-2.8pp | 94.7%+30.2pp | 94.6%+16.5pp | 96.7%+24.3pp | ||
| $149.45M+34.4% | $126.64M+13.6% | $116.42M-10.7% | $112.87M-6.3% | $111.23M-3.0% | ||
| $186.26M+44.2% | $163.9M+54.1% | $158.09M+66.8% | $137.62M+100.0% | $129.15M+117% | ||
| $350.76M+43.3% | $300.47M+36.0% | $293.74M+26.7% | $265.9M+36.7% | $244.84M+37.8% | ||
| -$107.08M+20.3% | -$105.96M-1.5% | -$139.56M+38.3% | -$145.2M+24.3% | -$134.28M+23.5% | ||
| -43.9%+77.5pp | -54.5%+35.0pp | -90.5%+3,752pp | -120.3%+6,898pp | -121.4%+7,975pp | ||
| $13.28M+14.4% | $12.94M-28.6% | $11.64M-45.9% | $11.74M-49.1% | $11.61M-49.4% | ||
| -$48.81M-3.0% | -$60.6M+7.1% | -$55.19M— | -$41.28M-250% | -$47.38M-147% | ||
| -$155.89M+14.2% | —— | -$194.76M+26.8% | -$186.48M-13.5% | -$181.66M-140% | ||
| $0-100% | —— | —— | -$1.55M— | $2.1M— | ||
| -$155.89M+15.2% | -$166.56M+1.8% | -$194.64M+27.2% | -$184.94M-12.6% | -$183.76M-143% | ||
| -64%+102pp | -85.6%+59.8pp | -126.2%+4,420pp | -153.2%+5,859pp | -166.2%+3,318pp | ||
| -$0.78+17.9% | -$0.84+4.5% | -$0.99+30.3% | -$0.95-10.5% | -$0.95-144% | ||
| -$106.03M+20.3% | -$104.77M-1.6% | -$138.13M+38.5% | -$143.8M+24.4% | -$132.96M+23.6% | ||
| -43.5%+76.7pp | -53.9%+34.5pp | -89.6%+3,730pp | -119.1%+6,843pp | -120.3%+7,904pp | ||
| -$107.08M+20.3% | -$105.96M-1.5% | -$139.56M+38.3% | -$145.2M+24.3% | -$134.28M+23.5% |
FAQ
- What is BridgeBio Pharma's revenue?
- BridgeBio Pharma (BBIO) generated $713.1M in revenue over the trailing twelve months, up 202.4% year over year.
- Is BridgeBio Pharma profitable?
- BridgeBio Pharma is not currently profitable: it reported a net loss of $702.0M over the trailing twelve months, a -98.5% net margin.
- What are BridgeBio Pharma's profit margins?
- Gross margin is 94.4% and operating margin is -69.8%, with a -98.5% net margin.
- What is BridgeBio Pharma's earnings per share?
- BridgeBio Pharma's diluted EPS over the trailing twelve months is $-3.56.
- Where does BridgeBio Pharma's income statement data come from?
- Every line is extracted from BridgeBio Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
